• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antimicrobial peptides derived from fusion peptides of influenza A viruses, a promising approach to designing potent antimicrobial agents

tetano

Editor, Senior Moderator
Chem Biol Drug Des. 2015 Jan 8. doi: 10.1111/cbdd.12511. [Epub ahead of print]
[h=1]Antimicrobial peptides derived from fusion peptides of influenza A viruses, a promising approach to designing potent antimicrobial agents.[/h] Wang J[SUP]1[/SUP], Zhong W, Lin D, Xia F, Wu W, Zhang H, Lin L, Liu S, He J.
[h=3]Author information[/h]

[h=3]Abstract[/h] The emergence and dissemination of antibiotic-resistant bacterial pathogens have spurred the urgent need to develop novel antimicrobial agents with different mode of action. In this respect, we turned several fusogenic peptides (FPs) derived from the hemaglutinin glycoproteins (HAs) of IAV into potent antibacterials by replacing the negatively or neutrally charged residues of FPs with positively charged lysines. Their antibacterial activities were evaluated by testing the MICs against a panel of bacterial strains including S. aureus, S. mutans, P. aerugenosa and E. coli. The results showed that peptides HA-FP-1, HA-FP-2-1 and HA-FP-3-1 were effective against both gram positive and gram negative bacteria with MICs ranging from 1.9 to 16.0 μM, while the toxicities toward mammalian cells were low. In addition, the mode of action and the secondary structure of these peptides were also discussed. These data not only provide several potent peptides displaying promising potential in development as broad antimicrobial agents, but also present a useful strategy in designing new antimicrobial agents. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] antimicrobial peptides ; fusion peptides; influenza A viruses

PMID: 25581878 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25581878
 
Back
Top Bottom